Hepatitis Clinical Trials

Showing 181-200 of 1,007 trials

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

NCT05953545

Background: Chronic hepatitis D is a serious liver disease caused by a virus. Currently, no medications are approved to treat chronic hepatitis D. Objective: To test a combination of 3 drugs in people with chronic hepatitis D. Eligibility: People 18 years or older with chronic hepatitis D. Design: Participants will be in the study about 2 years. They will have 3 inpatient stays of 3 to 5 days. Participants will be screened. They will have a physical exam with blood tests. They will have a test of their heart function and an ultrasound: a wand that uses sound waves to create images of the liver will be rubbed over the skin on their torso. Participants will stay in the clinic for a 3-day baseline visit. They will have imaging scans, an eye exam, and a visit with a reproductive specialist. They will have a liver biopsy: about 1 inch of liver tissue will be removed, either with a tube inserted through a vein in the neck, or with a needle inserted through the participant s side. Participants will take the study drugs for 48 weeks. Two of them are tablets taken twice a day at home; 1 is a shot administered once a week. Participants will begin taking the drugs during a 5-day stay in the clinic. Then they will have 15 outpatient visits while taking the drugs and 7 more after they finish. The last 3-day clinic stay will be 6 months after participants finish taking the drugs. The liver biopsy, imaging scans, and other tests will be repeated.

Chronic Hepatitis Delta

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Started May 2024

Bethesda, Maryland, United States

COMPLETEDNA

HCV Seek, Test and Rapid Treatment for Young PWID

NCT03627546

The purpose of this randomized study is to determine whether a community-based test and treat model of hepatitis C (HCV) care delivery will be superior to the usual care practice of referral to specialist clinics for the outcomes of sustained virologic response at 12 weeks after treatment and initiation of HCV treatment for persons who inject drugs (PWID) between ages 18 and 29 who are naïve to HCV treatment

Hepatitis CDrug Use

Weill Medical College of Cornell University39 participantsStarted Sep 2018

New York, New York, United States

Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis

HCV Seek, Test and Rapid Treatment for Young PWID

Related Searches

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis

Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus

Complex Exploratory Study of Alcohol-Associated Hepatitis

Standardising Care for Hepatitis Delta in the Netherlands

A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)

A Study Done by a Demonstrator and Two Professors in Public Health and Community Medicine Department in Faculty of Medicine in Assiut and New Valley University to Assess Knowledge, Attitude ,and Practice of Rural Population in a Remote Governorate ( New Valley ) Towards Hepatitis B and C Viruses

A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

Population-wide Research for HBV-related Liver Diseases in Maoming City

Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)

Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants

Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis

Prospective Cohort of HIV/HBV-coinfected Patients in Europe

Ablation of Hepatocellular Carcinoma: a Nationwide Study

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects